Howe & Rusling’s Seres Therapeutics MCRB Stock Holding History

Howe & Rusling’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5	Closed	–	–	859
2020 Q1	$0	Hold	5	–	–	﹤0.01%	836
2019 Q4	$0	Hold	5	–	–	﹤0.01%	853
2019 Q3	$0	Hold	5	–	–	﹤0.01%	846
2019 Q2	$0	Sell	5 -1	-17%	-$95	﹤0.01%	859
2019 Q1	$1K	Hold	6	–	–	﹤0.01%	750
2018 Q4	$1K	Buy	6 +2	+50%	+$280	﹤0.01%	751
2018 Q3	$1K	Hold	4	–	–	﹤0.01%	798
2018 Q2	$1K	Hold	4	–	–	﹤0.01%	752
2018 Q1	$1K	Sell	4 -1	-20%	-$192	﹤0.01%	860
2017 Q4	$1K	Hold	5	–	–	﹤0.01%	789
2017 Q3	$2K	Buy	+5	New	+$1.37K	﹤0.01%	764

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Howe & Rusling's MCRB Position: Q2 2020 in Review

Howe & Rusling sold out of Seres Therapeutics (MCRB) in Q2 2020, closing a stake of 5 shares.

Howe & Rusling first reported a position in MCRB in Q3 2017 and held it in 11 quarters. The position peaked at $2K in Q3 2017. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2020.

Howe & Rusling reported no remaining Seres Therapeutics position as of Q2 2020 after selling out during the quarter.
Howe & Rusling sold 5 Seres Therapeutics shares in Q2 2020.
Howe & Rusling first reported a position in Seres Therapeutics in Q3 2017 and held it in 11 quarters.
Howe & Rusling's Seres Therapeutics position peaked at $2K in Q3 2017.
93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2020.

Based on Howe & Rusling's 13F filing for Q2 2020, filed 15 Jul 2020.